Literature DB >> 25740704

Hyperuricemia, gout, and cardiovascular disease: an update.

Aryeh M Abeles1.   

Abstract

Across the globe, both gout and hyperuricemia have become increasingly common over the last few decades. The burden of gouty disease is made heavier by its association with several comorbid conditions, including hypertension, cardiovascular disease, and chronic kidney disease. Accruing evidence from prospective studies suggests that gout is an independent risk factor for developing cardiovascular disease and for higher cardiovascular mortality. While asymptomatic hyperuricemia does not seem to be an independent risk factor for cardiovascular disease, increasing data implicates hyperuricemia as a risk factor for developing incidental hypertension. Important questions that remain unanswered include whether addressing asymptomatic hyperuricemia forestalls the onset of hypertension, and whether treating gout with urate-lowering agents improves cardiovascular outcomes. This article reviews the most recent data regarding the relationship between hyperuricemia, gout, hypertension, and cardiovascular disease, as well as emerging evidence as to whether treatment of hyperuricemia and gout improves cardiovascular outcomes.

Entities:  

Mesh:

Year:  2015        PMID: 25740704     DOI: 10.1007/s11926-015-0495-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  41 in total

1.  Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008.

Authors:  Shao-Yuan Chuang; Shu-Chen Lee; Yao-Te Hsieh; Wen-Harn Pan
Journal:  Asia Pac J Clin Nutr       Date:  2011       Impact factor: 1.662

2.  Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.

Authors:  Marilda Mazzali; John Kanellis; Lin Han; Lili Feng; Yi-Yang Xia; Qiang Chen; Duk-Hee Kang; Katherine L Gordon; Susumu Watanabe; Takahiko Nakagawa; Hui Y Lan; Richard J Johnson
Journal:  Am J Physiol Renal Physiol       Date:  2002-06

Review 3.  Hyperuricemia and coronary heart disease: a systematic review and meta-analysis.

Authors:  Seo Young Kim; James P Guevara; Kyoung Mi Kim; Hyon K Choi; Daniel F Heitjan; Daniel A Albert
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-02       Impact factor: 4.794

4.  Uric acid concentration as a risk marker for blood pressure progression and incident hypertension: a Chinese cohort study.

Authors:  Tsan Yang; Chi-Hong Chu; Chyi-Huey Bai; San-Lin You; Yu-Ching Chou; Lee-Ching Hwang; Kuo-Liong Chien; Ta-Chen Su; Chin-Hsiao Tseng; Chien-An Sun
Journal:  Metabolism       Date:  2012-05-30       Impact factor: 8.694

5.  Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study.

Authors:  Mary A De Vera; M Mushfiqur Rahman; Vidula Bhole; Jacek A Kopec; Hyon K Choi
Journal:  Ann Rheum Dis       Date:  2010-02-02       Impact factor: 19.103

6.  Can animal models of disease reliably inform human studies?

Authors:  H Bart van der Worp; David W Howells; Emily S Sena; Michelle J Porritt; Sarah Rewell; Victoria O'Collins; Malcolm R Macleod
Journal:  PLoS Med       Date:  2010-03-30       Impact factor: 11.069

7.  Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort.

Authors:  Angelo L Gaffo; David R Jacobs; Femke Sijtsma; Cora E Lewis; Ted R Mikuls; Kenneth G Saag
Journal:  Ann Rheum Dis       Date:  2012-09-14       Impact factor: 19.103

8.  Long-term cardiovascular mortality among middle-aged men with gout.

Authors:  Eswar Krishnan; Kenneth Svendsen; James D Neaton; Greg Grandits; Lewis H Kuller
Journal:  Arch Intern Med       Date:  2008-05-26

9.  Independent impact of gout on mortality and risk for coronary heart disease.

Authors:  Hyon K Choi; Gary Curhan
Journal:  Circulation       Date:  2007-08-13       Impact factor: 29.690

10.  Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study.

Authors:  Victor C Kok; Jorng-Tzong Horng; Wan-Shan Chang; Ya-Fang Hong; Tzu-Hao Chang
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

View more
  39 in total

Review 1.  The effect of polymorphism of uric acid transporters on uric acid transport.

Authors:  Ze Wang; Tao Cui; Xiaoyan Ci; Fang Zhao; Yinghui Sun; Yazhuo Li; Rui Liu; Weidang Wu; Xiulin Yi; Changxiao Liu
Journal:  J Nephrol       Date:  2018-10-31       Impact factor: 3.902

2.  Longitudinal transition trajectory of gouty arthritis and its comorbidities: a population-based study.

Authors:  Chien-Fang Huang; Ju-Chi Liu; Hui-Chuan Huang; Shao-Yuan Chuang; Chang-I Chen; Kuan-Chia Lin
Journal:  Rheumatol Int       Date:  2016-12-21       Impact factor: 2.631

3.  Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout.

Authors:  Juan Meng; Yanchun Li; Xiaoxu Yuan; Yuewu Lu
Journal:  Rheumatol Int       Date:  2016-11-23       Impact factor: 2.631

4.  Structure-based design of a hyperthermostable AgUricase for hyperuricemia and gout therapy.

Authors:  Yi Shi; Ting Wang; X Edward Zhou; Qiu-Feng Liu; Yi Jiang; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2019-06-28       Impact factor: 6.150

5.  Changes of Treg/Th17 Ratio in Spleen of Acute Gouty Arthritis Rat Induced by MSU Crystals.

Authors:  Xiao-Juan Dai; Jin-Hui Tao; Xuan Fang; Yuan Xia; Xiao-Mei Li; Yi-Ping Wang; Xiang-Pei Li
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

6.  Systematic Structure-Activity Relationship (SAR) Exploration of Diarylmethane Backbone and Discovery of A Highly Potent Novel Uric Acid Transporter 1 (URAT1) Inhibitor.

Authors:  Wenqing Cai; Jingwei Wu; Wei Liu; Yafei Xie; Yuqiang Liu; Shuo Zhang; Weiren Xu; Lida Tang; Jianwu Wang; Guilong Zhao
Journal:  Molecules       Date:  2018-01-27       Impact factor: 4.411

7.  Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study.

Authors:  Ninad S Chaudhary; S Louis Bridges; Kenneth G Saag; Elizabeth J Rahn; Jeffrey R Curtis; Angelo Gaffo; Nita A Limdi; Emily B Levitan; Jasvinder A Singh; Lisandro D Colantonio; George Howard; Mary Cushman; Matthew L Flaherty; Suzanne Judd; Marguerite R Irvin; Richard J Reynolds
Journal:  Hypertension       Date:  2019-12-02       Impact factor: 10.190

8.  Molecular Elucidation of a Urate Oxidase from Deinococcus radiodurans for Hyperuricemia and Gout Therapy.

Authors:  Yi-Chih Chiu; Ting-Syuan Hsu; Chen-Yu Huang; Chun-Hua Hsu
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

9.  Comparative effects of quercetin, luteolin, apigenin and their related polyphenols on uric acid production in cultured hepatocytes and suppression of purine bodies-induced hyperuricemia by rutin in mice.

Authors:  Shin-Ichi Adachi; Mifuyu Oyama; Shinji Kondo; Kazumi Yagasaki
Journal:  Cytotechnology       Date:  2021-02-02       Impact factor: 2.040

Review 10.  Fructose intake and risk of gout and hyperuricemia: a systematic review and meta-analysis of prospective cohort studies.

Authors:  Joseph Jamnik; Sara Rehman; Sonia Blanco Mejia; Russell J de Souza; Tauseef A Khan; Lawrence A Leiter; Thomas M S Wolever; Cyril W C Kendall; David J A Jenkins; John L Sievenpiper
Journal:  BMJ Open       Date:  2016-10-03       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.